Next Breath Receives ISO/IEC 17025:2005 Accreditation From The American Association For Laboratory Accreditation
Next Breath Receives ISO/IEC 17025:2005 Accreditation.
Baltimore, Maryland (PRWEB) - Next Breath, LLC, a Specialty Contract Research Organization (CRO) with expertise in analytical testing of pulmonary, nasal drug, and ophthalmic delivery systems, announced today that the company received its ISO (the International Organization for Standardization) and IEC (the International Electrotechnical Commission) 17025:2005 accreditation from the American Association for Laboratory Accreditation (A2LA). Compliance with this standard provides a globally accepted basis for laboratory accreditation. The standard specifies the management and technical requirements to be met by testing and calibration laboratories in both the organization and management of quality.
The ISO/IEC 17025:2005 also covers testing and calibration performed using standard methods, non-standard methods, and laboratory-developed methods. This accreditation is another illustration of Next Breath’s commitment to quality and technical expertise, and adherence to the highest standards in quality management systems.
Julie Suman, President, says, “We are very pleased with this accreditation, which confirms Next Breath’s commitment to meeting and exceeding the highest quality standards. We work diligently to maintain regulatory standards and we have once again demonstrated our ability to sustain and continuously improve quality systems within our organization.”
A2LA is non-profit, non-governmental, public service, membership society. A2LA also offers programs for the accreditation of testing laboratories, calibration laboratories, inspection bodies, proficiency testing providers, medical testing laboratories, reference material producers and product certification bodies.
About Next Breath
Next Breath, a member of the AptarGroup, is a cGMP contract services organization for pharmaceutical, biotech and medical device companies that bring pulmonary, nasal, and ophthalmic drug products to market. Next Breath provides comprehensive solutions to the development processes from proof of concept to commercialization. Next Breath has led successful submissions for pulmonary and nasal drug products and devices in the US and international markets.
For more information please visit http://www.nextbreath.net or http://www.aptar.com
View original release here: http://www.prweb.com/releases/2013/2/prweb10435177.htm